Topical Psoralen Ultraviolet Light A Versus Narrow Band Ultraviolet Light B Treatment for Recalcitrant Dermatoses of the Hand
Topical Psoralen Ultraviolet Light A Versus Narrow Band Ultraviolet Light B Treatment for Recalcitrant Dermatoses of the Hand: A Prospective Randomized, Single-blinded Controlled Clinical Trial
研究概览
详细说明
Hand dermatoses is a common problem which is characterized by itchy, erythematous and scaly lesions often with a long lasting and relapsing course. Patients presenting with these severe cutaneous changes are classified as having severe recalcitrant hand dermatoses. Treatment is difficult with considerable number of patients do not or only partially respond to the current treatments. Current treatment regimens mainly involve the use of high potency topical corticosteroids, which has only limited affect. Systemic treatment modalities have been utilized but have serious side effects with limited improvement of disease.
Several studies have shown the therapeutic effectiveness of the combination of topical psoralen with long wavelength ultraviolet A radiation (PUVA) in treating hand dermatoses. Topical PUVA is commonly associated with mild local sunburn reactions that often necessitate temporarily withholding treatment or decreasing the light dose. This subsequently leads to a delay in response or a prolongation of the treatment. Long term side effects include aging of the skin, hyperpigmentation, and a small increased risk of skin cancer that is more common in systemic PUVA. Narrow band ultraviolet B (NB-UVB) has emerged recently as an important treatment for a variety of photoresponsive diseases including psoriasis and eczema. For most conditions (other than hand psoriasis/eczema) NB-UVB has been shown to have similar therapeutic results to PUVA with less side effects.
There are only a few studies published on the efficacy of NB-UVB for hand psoriasis/eczema. Our hypothesis is that NB-UVB and topical PUVA will result in at least comparable improvement in hand psoriasis/eczema with less side effects associated with NB-UVB. We plan on conducting a prospective single-blind randomized clinical trial to compare the efficacy and safety of topical PUVA and NB-UVB in treating hand psoriasis/eczema.
Study Objectives
- To compare the effect of topical PUVA and NB-UVB on visual cutaneous symptoms in patients presenting with recalcitrant hand dermatoses.
- To compare the side effect profile of topical PUVA and NB-UVB when treating patients with recalcitrant hand dermatoses.
研究类型
注册 (预期的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名:Harvey Lui, MD, FRCPC
- 邮箱:harvey.lui@ubc.ca
学习地点
-
-
British Columbia
-
Vancouver、British Columbia、加拿大、V5Z 4E8
- 招聘中
- The Skin Care Center, Vancouver General Hospital
-
接触:
- Harvey Lui, MD FRCPC
- 电话号码:16048754111
- 邮箱:harvey.lui@ubc.ca
-
首席研究员:
- Sunil Kalia, MD FRCPC
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Chronic symmetrical severe hand psoriasis and eczema (allowing up to 15% difference in surface area between both hands). These include patients that have received topical corticosteroids previously and may or may have not responded to treatment.
- Subjects should be 18 years old or older.
Exclusion Criteria:
- Any serious medical illness that will restrict the patient's ability to receive light treatments. That includes skin conditions, such as skin cancer or severe blistering conditions, or any serious medical conditions affecting the sensation of the extremities (eg. diabetic neuropathy, cervical stenosis).
- Patients known to have a photosensitivity disorder
- Patients with a history of intolerance to UVB and/or UVA light therapy.
- Any subject who is on treatment or was on treatment for hand psoriasis/eczema less than two (topical) or four (systemic/phototherapy) weeks prior to enrollment in the study.
- Pregnancy or breast-feeding.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:单组作业
- 屏蔽:单身的
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
有源比较器:NB-UVB
This single-blinded randomized bilateral left to right controlled comparison clinical trial of 24 weeks duration will compare the efficacy of NB-UVB to t-PUVA.
For each patient one hand will be randomly assigned to receive t-PUVA and the other hand will receive NB-UVB.
Each hand will receive treatment with either NB-UVB or topical PUVA three times weekly.
Treatment will be performed until complete or almost complete clearing of psoriasis/eczema or until 50 exposures (over 16 weeks) have been reached, whichever comes first.
|
|
有源比较器:Topical PUVA
This single-blinded randomized bilateral left to right controlled comparison clinical trial of 24 weeks duration will compare the efficacy of NB-UVB to t-PUVA.
For each patient one hand will be randomly assigned to receive t-PUVA and the other hand will receive NB-UVB.
Each hand will receive treatment with either NB-UVB or topical PUVA three times weekly.
Treatment will be performed until complete or almost complete clearing of psoriasis/eczema or until 50 exposures (over 16 weeks) have been reached, whichever comes first.
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
---|---|
The primary endpoint will be based on the change in visual cutaneous symptoms as measured by the modified ASI score
大体时间:Baseline, every four weeks up to 16 weeks, and at 24 weeks
|
Baseline, every four weeks up to 16 weeks, and at 24 weeks
|
次要结果测量
结果测量 |
大体时间 |
---|---|
The overall change in physical appearance of the hand will be assessed by the global assessment
大体时间:Every four weeks up to 16 weeks, and at 24 weeks
|
Every four weeks up to 16 weeks, and at 24 weeks
|
Adverse effects will be assessed every four weeks, including erythema, pruritus, and tanning. This will be assessed using the following scale: 0=none, 1=mild, 2=moderate, 3=severe.
大体时间:Every four weeks up to 16 weeks
|
Every four weeks up to 16 weeks
|
合作者和调查者
调查人员
- 首席研究员:Harvey Lui, MD, FRCPC、University of British Columbia
研究记录日期
研究主要日期
学习开始
初级完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- H12-02854
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.